Q-omics provides the consensus-scored MRPL14 profile across patient tissues and cancer cell-line models. MRPL14 expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MRPL14 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, MRPL14 protein abundance shows 22,116 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where MRPL14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPL14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPL14 survival associations across molecular data types. MRPL14 RNA expression shows survival associations in the most cancer types (29), followed by mutation status (1) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPL14 RNA expression–survival associations across cancer types. High MRPL14 expression shows unfavorable associations in UVM, ACC, KICH, KIRC and LAML, but favorable associations in OV. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MRPL14 RNA expression.
This table summarizes MRPL14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MRPL14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPL14 shows higher tumor expression in KIRC, THCA, HNSC, BLCA, COAD and LIHC. The KIRC box plot shows higher MRPL14 RNA expression in tumor versus normal tissue (log2 FC = +0.973, t-test p < 0.001).
This table shows molecular features associated with MRPL14 in patient tissues and cancer cell lines. In patient samples, MRPL14 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MRPL14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
